MOH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Molina Healthcare Inc (MOH) is not a good buy for a beginner investor with a long-term strategy at this time. The stock is facing significant financial and operational challenges, as evidenced by poor Q4 financial performance, negative sentiment in analyst ratings, and ongoing legal issues. Additionally, technical indicators are bearish, and there is no strong signal from Intellectia Proprietary Trading Signals to suggest a short-term opportunity. It would be prudent to wait for clearer signs of recovery or stability before considering an investment.
The technical indicators for MOH are bearish. The MACD is negatively expanding below zero, the RSI is neutral at 40.611, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below key pivot levels, with support at 135.114 and resistance at 142.887. These indicators suggest a downward trend with no clear reversal signal.
The company reported an 8.34% YoY revenue increase in Q4 2025, which is a positive sign of top-line growth.
Gross margin also fell by 23.79%. Analysts have downgraded the stock and lowered price targets, citing concerns about Medicaid and health insurance exchange pressures, as well as poor Q4 performance. Additionally, there is an ongoing class action lawsuit and investigation into the company.
In Q4 2025, revenue increased by 8.34% YoY to $11.375 billion. However, net income dropped to -$160 million (-163.75% YoY), EPS fell to -3.16 (-171.17% YoY), and gross margin declined to 10.51% (-23.79% YoY). These results indicate severe profitability challenges.
Analysts have generally downgraded the stock and lowered price targets. UBS raised the target to $151 but maintained a Neutral rating. Mizuho lowered the target to $180 but kept an Outperform rating. Other firms like Morgan Stanley, Wells Fargo, Truist, JPMorgan, Goldman Sachs, Deutsche Bank, and Barclays have significantly reduced price targets and expressed concerns about the company's financial performance and guidance.
